Law360, New York (September 11, 2009, 4:03 PM ET) -- The entire board of directors at Pfizer Inc. and certain executives have been smacked with a shareholder derivative lawsuit alleging they harmed the company by promoting prescription drugs for unapproved, off-label uses.
The suit was filed Sept. 10 in the U.S. District Court for the Southern District of New York, just eight days after Pfizer agreed to pay a record $2.3 billion in civil and criminal fines.
It accuses 17 individual defendants, including CEO Jeffrey B. Kindler and CFO Frank D'Amelio, of breach of fiduciary duties...
Derivative Suit Filed In Wake Of Record Pfizer Payout
To view the full article, take a free trial now.
